Review coverage on Peptide News Digest pulls in NeurologyLive, Pharmacy Times, Medscape, and similar review-style articles that synthesize multiple readouts into a single piece. They tend to be the most-shared writeups in the practitioner-facing press.
Key reads: NeurologyLive's GLP-1 repositioning review across Alzheimer's, Parkinson's, multiple sclerosis, and stroke (drawing on EVOKE, exenatide and lixisenatide PD trials, and the migraine/dementia work); Medscape's FAERS analysis of GLP-1 safety across the class; and various Pharmacy Times pieces on cardiometabolic outcomes.
Stories here cover the review-style synthesis pieces. See specific drug or indication tags for the underlying primary readouts.
A January 2026 Frontiers in Cellular and Infection Microbiology review synthesized the case for antimicrobial peptides (AMPs) as the most promising response to antimicrobial resistance, which is responsible for nearly 5 million deaths annually and projected to double by 2050. The review emphasizes that AMPs' rapid, multi-target mechanism — primarily physical membrane disruption — produces significantly lower incidence of resistance emergence than traditional small-molecule antibiotics. The pipeline now exceeds 150 active candidates spanning AI-designed AMPs, lysin-derived peptides, and venom-derived sequences.
A comprehensive review in Frontiers in Drug Delivery examines the barriers to oral peptide bioavailability — enzymatic degradation, poor membrane permeability, and first-pass metabolism — and maps emerging solutions including permeation enhancers, nanoparticle encapsulation, mucoadhesive systems, and microRNA-based approaches that are advancing toward clinical translation.
A new review highlights GLP-1 RAs achieving a 55% reduction in apnea-hypopnea index and 14.9% mean weight loss in non-diabetic populations, with pleiotropic effects across cardiovascular, renal, and skeletal systems.